VolitionRX (NYSEAMERICAN:VNRX) Issues Quarterly Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Thursday. The medical research company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.17, FiscalAI reports. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.71 million.

VolitionRX Trading Down 9.4%

VolitionRX stock traded down $0.02 during mid-day trading on Thursday, hitting $0.18. The company had a trading volume of 857,984 shares, compared to its average volume of 2,845,635. The company has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.05 and a beta of 1.16. VolitionRX has a 12-month low of $0.16 and a 12-month high of $7.90. The company’s fifty day moving average is $0.24 and its 200-day moving average is $1.97.

Analyst Upgrades and Downgrades

Separately, Benchmark reissued a “hold” rating on shares of VolitionRX in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.00.

About VolitionRX

VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions. The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions.